Valuation: Quanterix Corporation

Market Cap 187M 163M 151M 138M 262M 17.97B 266M 1.8B 706M 8.78B 701M 685M 30.3B P/E 2026 *
-3.07x
P/E 2027 * -2.99x
Enterprise Value 187M 163M 151M 138M 262M 17.97B 266M 1.8B 706M 8.78B 701M 685M 30.3B EV / Sales 2026 *
1.1x
EV / Sales 2027 * 0.99x
Free-Float
93.7%
Yield 2026 *
-
Yield 2027 * -
1 day-6.60%
1 week-0.50%
Current month-8.33%
1 month+29.41%
3 months+16.47%
6 months-46.49%
Current year-37.74%
1 week 3.7
Extreme 3.695
4.42
1 month 2.95
Extreme 2.95
4.57
Current year 2.4
Extreme 2.395
8.77
1 year 2.4
Extreme 2.395
8.77
3 years 2.4
Extreme 2.395
29.7
5 years 2.4
Extreme 2.395
60.92
10 years 2.4
Extreme 2.395
92.57
Manager TitleAgeSince
Chief Executive Officer 59 2026-01-18
Director of Finance/CFO 50 2026-06-21
Chief Operating Officer - 2026-05-13
Director TitleAgeSince
Director/Board Member 63 2022-06-05
Chairman 64 2025-03-23
Director/Board Member 48 2024-08-18
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Fiscal year

Director

16,146 0.0347%
7/8/26 Fiscal year

Director

16,146 0.0347%
7/1/26 Free

Director

3,456 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
-6.60%-0.50%-30.04%-83.40% 187M
+1.48%+3.52%+30.48%+2.61% 202B
+2.10%+4.61%+6.06%-14.77% 145B
+3.43%-2.24%-21.52%+13.65% 142B
+3.67%-0.82%-56.76%-15.86% 66.32B
+0.65%-3.82%+15.37%-5.93% 50.58B
+0.58%+2.34%-24.02%-31.26% 44.81B
+1.03%+1.88%+19.99%+13.65% 38.44B
+0.87%+0.28%+30.61%+39.67% 37.13B
+3.96%+1.55%-12.92%-19.70% 29.89B
Average +0.70%+0.97%-4.28%-10.13% 75.68B
Weighted average by Cap. +1.73%+1.83%+1.87%-1.36%

Financials

2026 *2027 *
Net sales 170M 148M 137M 126M 238M 16.37B 243M 1.64B 643M 7.99B 638M 624M 27.6B 189M 165M 153M 140M 265M 18.18B 270M 1.82B 715M 8.88B 709M 693M 30.66B
Net income -61.09M -53.4M -49.39M -45.32M -85.77M -5.89B -87.26M -589M -231M -2.87B -229M -224M -9.92B -63.78M -55.75M -51.56M -47.31M -89.55M -6.15B -91.1M -615M -242M -3B -240M -234M -10.36B
Net Debt - -
Logo Quanterix Corporation
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Employees
450
Date Price Change Volume
26-07-16 US$3.960 -6.60% 1,020,737
26-07-15 US$4.240 +3.92% 639,503
26-07-14 US$4.080 +5.15% 584,745
26-07-13 US$3.880 0.00% 289,605
26-07-10 US$3.880 -2.51% 357,380
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.960USD
Average target price
4.333USD
Spread / Average Target
+9.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. QTRX Stock